Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  Issue: February 2017  |  February 16, 2017

TABLE 2: Histopathologic Features of Patients with Erdheim-Chester

(click for larger image)
TABLE 2: Histopathologic Features of Patients with Erdheim-Chester

Because of concern for IgG4-related disease, the lung biopsy tissue was retrospectively stained for IgG4+ plasma cells. Referral to the MGH Division of Rheumatology was made. The IgG4+ cell count was 21/hpf with 43% IgG4/IgG ratio. All available pathologic material, including specimens from the pancreas, liver, lung and bone marrow, was reviewed by Vikram Deshpande, MD.

The lung biopsy showed CD68-positive, S-100-negative, CD1a-negative foamy histiocytes not previously appreciated. All were consistent with a diagnosis of ECD.

Figures 1A (left) & B (right): Patient 1

Figures 1A (left) & B (right): Patient 1

A clinical decision was made to start 8 mg/kg tocilizumab intravenously every four weeks; prednisone was tapered from 20 mg to 10 mg daily over a three-month period. A repeat PET-CT showed lungs with markedly less uptake and stable flu­deoxyglucose avidity in the pancreas and bone (see Figure 2D). Repeat CT scans showed vast improvement in inflammation intra-abdominally and complete resolution of pulmonary ground-glass opacities (see Figure 4A).

Figures 1C (left) & D (right): Patient 2

Figures 1C (left) & D (right): Patient 2
Figures 1A–D show the computed tomography (CT) on Patients 1 and 2. 1A is a CT scan of Patient 1 without contrast showing pulmonary ground-glass opacities. 1B is a CT scan of Patient 1 showing a sclerotic lesion at T10. 1C is a CT scan of Patient 2 with contrast showing soft-tissue rind around the kidneys, also seen in Patient 1. 1D is a CT scan of Patient 2 with contrast showing soft-tissue infiltration around the abdominal aorta.

The patient has been in remission without repeat hospitalizations for five years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patient 2: A 54-year-old man presented in 2014 to his physician with back and flank pain, low-grade fever and a 7 kg weight loss. Medical history included resolved depression treated with antidepressants, no prior surgeries and no allergies. His family history was unremarkable. He was a married veterinarian with two children and a non-smoker with occasional alcohol use.

On review of systems, he had low-grade fevers, back pain, flank pain and pain in the rhomboid area. He had no neuro­logical complaints, vision symptoms, swollen lymph nodes or cardiopulmonary symptoms. He denied urinary hesitancy or other voiding symptoms. There were no rashes.

Vital signs were normal. Positive findings included lacrimal gland enlargement, goiter (left greater than right side) and several enlarged lymph nodes (up to 2 cm in his axilla and 1.5 cm in the inguinal area). His abdomen was mildly distended, nontender, with no organomegaly. There was no costovertebral angle tenderness. There were hyper­pigmented plaques on his distal extremities. Laboratory studies revealed an increased creatinine level, and an ultrasound demonstrated bilateral hydronephrosis. Bloodwork in September 2015 showed WBC 10.7 x 109/L, Hct 35%, platelets 348 x 109 (normal <350), creatinine 98  μmol/L, total protein 60 g/L, albumin 33 g/L, ALP 164 U/L, AST 35 U/L, ALT 74 U/L and high-sensitivity C-reactive protein (HS-CRP) 105 mg/L (normal <5). A lipid panel was normal. He was hepatitis B immune. Urinalysis showed no protein, trace hemoglobin, 11–30 WBCs per HPF, 1–3 RBCs per HPF and a few epithelial cells. The patient’s IgG subclasses were normal.

Page: 1 2 3 4 5 6 7 8 9 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-interleukincase reportClinicalDiagnosisDiseaseErdheim-ChesterinflammatoryinterferonPathogenesistherapyTreatment

Related Articles

    Systemic Juvenile Idiopathic Arthritis

    May 9, 2012

    Changing treatment paradigms in the biologic era

    Case Report: Intermittent Fevers in a Patient with pJIA

    April 15, 2022

    A 26-year-old woman presented to our emergency department (ED) with intermittent fevers, nausea and vomiting. She had a past medical history of well-controlled, anti-nuclear antibody positive and rheumatoid factor negative polyarticular juvenile idiopathic arthritis (pJIA) and Crohn’s disease. Her maintenance treatment consisted of monthly intravenous infliximab, 10 mg of oral methotrexate weekly and 20 mg…

    Arthritis Drug Anakinra Shows Promise in COVID-19

    May 12, 2020

    NEW YORK (Reuters Health)—Treatment with the interleukin-1 blocker anakinra appears to improve respiratory symptoms and reduced signs of cytokine storm in nearly three-quarters of patients with acute respiratory distress and cytokine release syndrome from COVID-19 in a small retrospective study from Italy. “Our study is the first to suggest that a high dose of the…

    Case Report: Adult-Onset Still’s Disease with Complications

    February 14, 2023

    The following report outlines a case of newly diagnosed adult-onset Still’s disease (AOSD) complicated by macrophage activation syndrome (MAS) in a previously healthy and active 32-year-old man who had emigrated from Africa to the U.S. Case A man with no prior medical history presented with acute-onset polyarthritis, fevers and fatigue that began one month previously….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences